Compare iShares MSCI South Korea ETF (EWY) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Oscar Health Inc — how do they compare? iShares MSCI South Korea ETF trades at $177.22 (market cap $26.25B), while Oscar Health Inc trades at $33.37 (market cap $10.22B). The key difference: iShares MSCI South Korea ETF is far larger — about 2.6× Oscar Health Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and Oscar Health Inc for 15 Days on average.
| EWY | OSCR | |
|---|---|---|
Market Cap | $26.25B | $10.22B |
Volume | 19,056,075 | 4,123,394 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $33.81 |
52-Week Low | $80.72 | $10.85 |
Typical Hold Time | 47 Days | 15 Days |
Enterprise Value | — | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) trades at $176.33, down 4.02% amid broad Asian market weakness driven by rising oil prices and global bond yields. The ETF shows bearish technical signals with moving averages indicating selling pressure, though oversold RSI levels suggest potential near-term support. EWY remains heavily concentrated in Samsung and SK hynix, benefiting from AI-driven memory demand but vulnerable to semiconductor cycle volatility.
Outlook remains cautious given high concentration risk and macroeconomic headwinds, though strong AI infrastructure spending provides fundamental support. Key risks include semiconductor cycle sensitivity, Korean market volatility, and global interest rate pressures. The ETF's 148% YoY gain highlights both opportunity and vulnerability to corrections.
OSCR trades at $33.10, up 0.58% with a bullish technical signal and strong institutional support. Recent earnings show volatility with Q1 and Q2 2026 beats but a Q4 2025 miss. Revenue grew from $11.7B in 2025 to $15.3B in 2026, with net income turning positive at $551M. Analyst consensus is mixed with 30.77% buy ratings and a $34.00 price target, slightly above current levels.
The outlook is cautiously optimistic with strong revenue growth and profitability improvements, though risks include medical cost pressures and competitive ACA market dynamics. Upside potential exists if margin expansion continues, but investors should monitor execution against guidance and healthcare sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
